No Data
China Galaxy Securities: A review of the fifth set of standards on the Star has significantly boosted investment in the pharmaceutical industry.
Future reforms in diversified payment for commercial insurance are expected to bring marginal improvements from a policy perspective, and there are good long-term investment opportunities in pharmaceutical innovation and related industries.
Zhongtai: The implementation of the tenth batch of centralized procurement is expected to accelerate the clearance of generic drugs. Commercial insurance is an important incremental logic in the pharmaceutical Sector.
It is recommended to keep a close eye on the progress and implementation of commercial insurance, as improvements in the payment sector are expected to bring about a significant market trend in the Pharmaceutical Sector, with opportunities for recovery and reversal in hospital pharmaceuticals, diagnostics, and Medical Devices.
Improved Earnings Required Before Shanghai Allist Pharmaceuticals Co., Ltd. (SHSE:688578) Stock's 25% Jump Looks Justified
shanghai allist pharmaceuticals co., ltd. (688578.SH): plans to use AI models to predict the interactions of biological molecules
Geelonghui December 4th | Shanghai Allist Pharmaceuticals Co., Ltd. (688578.SH) stated on the interactive platform that the company's drug design team pays high attention to the application areas and development trends of AI technology, planning to use AI models to predict the interactions of biological molecules, in order to guide molecular design to improve the efficiency of new drug research.
Shanghai Allist Pharmaceuticals Co., Ltd.'s (SHSE:688578) Intrinsic Value Is Potentially 96% Above Its Share Price
Shanghai Allist Pharmaceuticals Co., Ltd.'s (SHSE:688578) Stock Price Dropped 7.1% Last Week; Private Companies Would Not Be Happy
Shanghai Allist Pharmaceuticals Co., Ltd.'s (SHSE:688578) Shareholders Might Be Looking For Exit
No Data
